ARDSのニュース
AstraZeneca Axes Pneumonia Drug Pact With Aridis 2023/03/29 17:17:26 Benzinga
AstraZeneca plc (NASDAQ: AZN ) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS ). With the license terminated for AR-320 (suvratoxumab), the ongoing AR-320-003 Phase 3 clinical study must be put on hold, the company said in an SEC filing. The SAATELLITE-2 trial enrolled the first patient in … Full story available on Benzinga.com
Why Aridis Pharmaceuticals Shares Are Diving 2023/03/14 15:24:52 Benzinga
Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) shares are trading lower by 23.34% to $0.42 Tuesday morning after the company announced a $2.28 million registered direct offering. The company has entered a definitive agreement for the … Full story available on Benzinga.com
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday''s Mid-Day Session 2023/03/13 17:22:23 Benzinga
Gainers Provention Bio, Inc. (NASDAQ: PRVB ) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. Hycroft Mining Holding Corporation (NASDAQ: HYMC ) surged 41.6% to $0.4390. Calliditas Therapeutics AB (NASDAQ: CALT ) shares gained 33.7% to $22.73 after the company announced the primary endpoint was successfully met in the Phase 2 NefIgArd trial evaluating Nefecon in IgA nephropathy. Clearmind Medicine Inc. (NASDAQ: CMND ) gained 31.7% to $4.53. Cipher Mining Inc. (NASDAQ: CIFR ) rose 30.2% to $1.7195. EUDA Health Holdings Limited (NASDAQ: EUDA ) gained 30% to $2.62. ZIM Integrated Shipping Services Ltd. (NYSE: ZIM ) surged 23.7% to $24.20 after the company reported a fourth-quarter FY22 sales decline of 37% year-on-year to $2.19 billion, beating the consensus of $2.11 billion. Austin Gold Corp. (NYSE: AUST ) rose 22.2% to $1.10 Iris Energy Limited (NASDAQ: IREN ) rose 22% to $3.16. Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS ) gained 20% to $0.5530 after the company announced the primary and secondary endpoints were met in the Phase 2a study of AR-501 in cystic fibrosis patients.
Why Aridis Pharmaceuticals Shares Are Soaring Today 2023/03/13 13:15:27 Benzinga
Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections. The study evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol and was conducted with funding support from the Cystic Fibrosis Foundation. AR-501 is being developed as a once-per-week … Full story available on Benzinga.com
Aridis Skyrockets on Impressive Data In Cystic Fibrosis 2023/03/13 13:14:50 TipRanks
Shares of biopharmaceutical company Aridis Pharmaceuticals (NASDAQ:ARDS) are soaring higher today after the company announced preliminary top-line …
Aridis Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07, revenue of $1.18M misses by $0.82M 2022/05/16 20:34:55 Seeking Alpha
Aridis Pharmaceuticals press release (ARDS): Q1 GAAP EPS of -$0.44 beats by $0.07.Revenue of $1.18M misses by $0.82M.
Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update 2022/05/16 20:05:00 PR Newswire
Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening…
Aridis Pharmaceuticals GAAP EPS of -$0.92 misses by $0.59, revenue of $0.57M misses by $1.33M 2022/04/01 11:24:43 Seeking Alpha
Aridis Pharmaceuticals press release (ARDS): Q4 GAAP EPS of -$0.92 misses by $0.59.Revenue of $0.57M misses by $1.33M.
Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update 2022/03/31 22:04:00 PR Newswire
Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif., March 31, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a…
Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study 2022/02/17 16:41:34 Benzinga
Aridis Pharmaceuticals Inc''s (NASDAQ: ARDS ) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant . Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, … Full story available on Benzinga.com
Aridis Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07, revenue of $1.18M misses by $0.82M 2022/05/16 20:34:55 Seeking Alpha
Aridis Pharmaceuticals press release (ARDS): Q1 GAAP EPS of -$0.44 beats by $0.07.Revenue of $1.18M misses by $0.82M.
Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update 2022/05/16 20:05:00 PR Newswire
Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening…
Aridis Pharmaceuticals GAAP EPS of -$0.92 misses by $0.59, revenue of $0.57M misses by $1.33M 2022/04/01 11:24:43 Seeking Alpha
Aridis Pharmaceuticals press release (ARDS): Q4 GAAP EPS of -$0.92 misses by $0.59.Revenue of $0.57M misses by $1.33M.
Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update 2022/03/31 22:04:00 PR Newswire
Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif., March 31, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a…
Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study 2022/02/17 16:41:34 Benzinga
Aridis Pharmaceuticals Inc''s (NASDAQ: ARDS ) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant . Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, … Full story available on Benzinga.com